SynAct Pharma has drawn down the remaining SEK50m under its convertible financing facility with Fenja Capital, bringing total utilisation to SEK100m. The additional funding strengthens SynAct’s liquidity position and provides greater financial flexibility to advance resomelagon’s clinical development, particularly preparations for Phase III in rheumatoid arthritis and ongoing partnering discussions. The new convertibles carry a conversion price of SEK24.60/share, matching the initial tranche, with the full facility maturing in December 2027. Full conversion would result in c 6.74% shareholder dilution. Management had previously guided to cash headroom into Q427, which we understand already accounted for this latest cash inflow.
Financials | Comment
Healthcare | Comment
Consumer | Comment
Healthcare | Comment
Industrials | Comment